🍽️ methylatropine nitrate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antispasmodic Action: Methylatropine nitrate acts as an antimuscarinic agent, meaning it blocks the action of acetylcholine at muscarinic receptors. By doing so, it inhibits the involuntary contractions of smooth muscles, particularly in the GI tract and the urinary system. This action helps to relieve spasms and cramps in these organs.

  2. Gastrointestinal Disorders: Methylatropine nitrate is commonly used to alleviate symptoms associated with gastrointestinal disorders such as irritable bowel syndrome (IBS), gastric ulcers, diverticulitis, and other conditions characterized by spasms or cramps in the GI tract. It can help reduce abdominal pain, bloating, and discomfort.

  3. Urinary Disorders: Methylatropine nitrate may also be used to treat urinary disorders characterized by involuntary muscle contractions, such as overactive bladder or urinary incontinence. By reducing bladder spasms, it can help improve urinary control and reduce urgency and frequency of urination.

  4. Preoperative Medication: Methylatropine nitrate is sometimes administered before surgery to reduce secretions in the respiratory and GI tracts. By drying up these secretions, it can help prevent complications such as aspiration pneumonia during anesthesia.

  5. Adjunctive Therapy: In some cases, methylatropine nitrate may be used as adjunctive therapy in the treatment of certain medical conditions, particularly those involving spasms or hypersecretion.

  6. Side Effects: Like all medications, methylatropine nitrate may cause side effects. Common side effects may include:

    • Dry mouth
    • Blurred vision
    • Urinary retention
    • Constipation
    • Tachycardia (rapid heartbeat)
    • Dilated pupils (mydriasis)
    • Dizziness or lightheadedness
    • Confusion or cognitive impairment
    • Flushing or dry skin
  7. Contraindications: Methylatropine nitrate is contraindicated in individuals with a known hypersensitivity to the medication or its components. It should also be used with caution in patients with certain medical conditions such as glaucoma, prostatic hypertrophy, or obstructive urinary disorders.

  8. Dosage and Administration: The dosage of methylatropine nitrate is individualized based on the patient's condition and response to treatment. It is typically administered orally in the form of tablets or as an injection for intramuscular or intravenous use.

  9. Monitoring: Patients taking methylatropine nitrate should be monitored for adverse effects, particularly those related to anticholinergic activity such as dry mouth, urinary retention, and constipation. Dosage adjustments may be necessary based on the patient's response and tolerance to the medication.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of methylatropine nitrate,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces

Bacteria Impacted by methylatropine nitrate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Escherichia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Ruminococcus bromii species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Coprococcus comes species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lachnospira eligens species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of methylatropine nitrate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.1 0.1 0
Allergic Rhinitis (Hay Fever) 0.2 0.2
Allergies 0.4 0.2 1
Allergy to milk products 0.5 0.2 1.5
Alzheimer's disease 0.3 0.4 -0.33
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.4 0.5 -0.25
Ankylosing spondylitis 0.6 0.2 2
Anorexia Nervosa 0.2 -0.2
Antiphospholipid syndrome (APS) 0.4 0.4
Atherosclerosis 0.1 0.1
Atrial fibrillation 0.2 0.2 0
Autism 0.5 0.5 0
benign prostatic hyperplasia 0.2 0.2
Bipolar Disorder 0.3 0.2 0.5
Carcinoma 0.3 0.1 2
Celiac Disease 0.4 0.2 1
Cerebral Palsy 0.1 -0.1
Chronic Fatigue Syndrome 0.2 0.2 0
Chronic Kidney Disease 0.3 0.1 2
Chronic Obstructive Pulmonary Disease (COPD) 0.1 -0.1
Chronic Urticaria (Hives) 0.6 0.6
Coagulation / Micro clot triggering bacteria 0.6 0.1 5
Colorectal Cancer 0.7 0.7
Constipation 0.2 0.2
Coronary artery disease 0.1 0.1 0
COVID-19 0.7 0.5 0.4
Crohn's Disease 0.8 0.3 1.67
cystic fibrosis 0.6 0.6
deep vein thrombosis 0.6 0.1 5
Depression 0.6 0.5 0.2
Eczema 0.2 0.2
Endometriosis 0.7 0.2 2.5
Epilepsy 0.2 0.2
Fibromyalgia 0.1 -0.1
Functional constipation / chronic idiopathic constipation 0.8 0.2 3
gallstone disease (gsd) 0.3 0.3
Generalized anxiety disorder 0.6 0.1 5
Gout 0.1 -0.1
Hashimoto's thyroiditis 0.1 0.1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.4 0.1 3
hyperglycemia 0.2 0.2
hypertension (High Blood Pressure 0.3 0.1 2
Hypothyroidism 0.1 -0.1
IgA nephropathy (IgAN) 0.1 -0.1
Inflammatory Bowel Disease 0.6 0.5 0.2
Insomnia 0 0
Intelligence 0.1 0.1
Intracranial aneurysms 0.1 0.1
Irritable Bowel Syndrome 0.7 0 0
Liver Cirrhosis 0.4 0.2 1
Long COVID 0.4 0.6 -0.5
Low bone mineral density 0.1 -0.1
Lung Cancer 0.2 0.1 1
ME/CFS with IBS 0.1 -0.1
ME/CFS without IBS 0.1 0.1
Metabolic Syndrome 0.8 0.2 3
Mood Disorders 0.8 0.5 0.6
Multiple Sclerosis 0.1 0.2 -1
Multiple system atrophy (MSA) 0.1 -0.1
Neuropathy (all types) 0.2 -0.2
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 0.2 0
Obesity 0.5 0.2 1.5
obsessive-compulsive disorder 0.9 0.2 3.5
Osteoarthritis 0.2 0.1 1
Osteoporosis 0.3 0.3
Parkinson's Disease 0.5 0.4 0.25
Polycystic ovary syndrome 0.3 0.2 0.5
Postural orthostatic tachycardia syndrome 0.1 -0.1
Psoriasis 0.5 0.1 4
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.4 0.1 3
Rosacea 0.3 0.3
Schizophrenia 0.2 0.2 0
scoliosis 0.1 0.2 -1
Sjögren syndrome 0.2 0.2
Sleep Apnea 0.2 0.1 1
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 0.4
Stress / posttraumatic stress disorder 0.4 0.1 3
Systemic Lupus Erythematosus 0.3 0.2 0.5
Tic Disorder 0.1 0.1
Type 1 Diabetes 0.4 0 0
Type 2 Diabetes 0.8 0.6 0.33
Ulcerative colitis 0.6 0.1 5
Unhealthy Ageing 0.2 0.1 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.